SightLife Surgical Rebrands as CorneaGen, Offers New Products

April 13, 2018: By Jon Swedien

SightLife Surgical announced April 12 that it has changed its name to CorneaGen.

The Seattle-based subsidiary of the nonprofit SightLife also announced it has three new product offerings:

–Tissue storage media with antifungal amphotericin B (Ampho B), which is used to combat rising rates of post-transplant fungal infections;

–The Geuder Preloaded Glass Cannula for Descemet’s membrane endothelial keratoplasty (DMEK);

–Intacs corneal implants for keratoconus.

The company in the past 18 months has begun offering more products and services aimed at transforming how corneal surgeons treat the cornea, President and CEO Monty Montoya said. The company decided to change its name to reflect its focus, Montoya said.

In March, the company also acquired the KAMRA corneal inlay from AcuFocus.

Regarding Ampho B, CorneaGen said surgeons across the US have long requested it. CorneaGen is now the first US company to offer storage media with Ampho B, the company said.

The Geuder Preloaded Glass Cannula for DMEK is the first specifically designed for preloaded cornea tissue, CorneaGen said. The device uses a locking system that minimizes damage to the tissue during transport, CorneaGen said.

Intacs corneal implants are designed to reduce or eliminate myopia and astigmatism in keratoconus patients, CorneaGen said. Intacs corneal implants help restore functional vision and potentially defer the need for a corneal transplant. CorneaGen said it has signed an exclusive US distribution agreement for Intacs with Addition Technology, an AJL Ophthalmics subsidiary.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT